Valuation : Personalis, Inc.

Market Cap 1.82B 1.57B 1.47B 1.35B 2.53B 173B 2.55B 17.46B 6.8B 87.96B 6.85B 6.7B 291B P/E 2026 *
-15.6x
P/E 2027 * -18.1x
Enterprise Value 1.65B 1.42B 1.33B 1.21B 2.28B 157B 2.3B 15.76B 6.13B 79.39B 6.18B 6.04B 263B EV / Sales 2026 *
20x
EV / Sales 2027 * 15.7x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.99%
1 week-1.82%
Current month+32.31%
1 month+32.31%
3 months+48.76%
6 months+93.19%
Current year+110.43%
1 week 16.55
Extreme 16.55
17.64
1 month 12.35
Extreme 12.35
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.67
Extreme 4.6713
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
President 55 13/03/2026
Chief Executive Officer 65 31/12/2022
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/7/26 Exercice

Chairperson

300,000 0.2865%
9/7/26 Exercice

Chief Executive Officer

300,000 0.2865%
29/6/26 Exercice

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-1.82%+248.23%+820.33% 1.82B
-1.23%-1.91%+0.98%+17.94% 50.47B
-2.08%-3.53%+416.34%+500.85% 44.56B
-0.65%+0.21%+41.93%+17.13% 43.08B
-2.64%-3.88%+7.68%+72.27% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.85%-4.95%+24.51%+118.06% 16.77B
+6.59%+4.94% - - 16.28B
+0.25%-0.98%+11.63%+27.62% 14.58B
-1.62%-3.77%+78.19%+38.93% 13.92B
Average -0.65%-1.83%+94.20%+184.44% 27.64B
Weighted average by Cap. -0.97%-1.09%+90.19%+126.68%

Financials

2026 *2027 *
Net sales 82.47M 71M 66.67M 60.86M 114M 7.85B 115M 790M 307M 3.98B 310M 303M 13.17B 110M 94.88M 89.09M 81.33M 153M 10.49B 154M 1.06B 411M 5.32B 414M 405M 17.61B
Net income -115M -99.1M -93.05M -84.94M -160M -10.95B -161M -1.1B -429M -5.55B -432M -423M -18.39B -102M -87.78M -82.42M -75.24M -141M -9.7B -142M -977M -380M -4.92B -383M -374M -16.29B
Net Debt -178M -153M -144M -131M -246M -16.9B -248M -1.7B -662M -8.57B -667M -652M -28.37B -91.04M -78.39M -73.6M -67.19M -126M -8.66B -127M -872M -339M -4.39B -342M -334M -14.54B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
01/09/26 USD 16.72 -2.05% 1,315,283
28/08/26 USD 17.07 +1.61% 2,973,181
27/08/26 USD 16.80 -1.64% 4,943,828
26/08/26 USD 17.08 -0.99% 2,175,012
25/08/26 USD 17.25 +1.11% 2,897,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
17.07USD
Average target price
15.44USD
Spread / Average Target
-9.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock